CTLA4 and neoplasm: By generating a fresh wave of tumor-specific T cells, ICD can sensitize “cold” tumors (lacking immune infiltrate) to ICIs like anti-PD-1 and anti-CTLA-4 antibodies, which work by “releasing the brakes” on already-present T cells.